Piramal Pharma (PPLPHARMA) Share Price Falls 2.71% Today to Rs 212.20

Piramal Pharma Share Price was at Rs 212.20 on 10 September 2026 at 3:23:03 PM IST, down 2.71% for the day. The stock had closed at Rs 218.10 in the previous session, so the decline amounted to Rs 5.90, while the company’s market capitalisation stood at Rs 30,168.35 crore.

For investors following Piramal Pharma Share Price Today, the confirmed data shows a clear same-day decline but does not identify any company-specific reason behind it. Even without a stated catalyst, the move remains relevant because Piramal Pharma is a large-cap name in the Healthcare sector and the Pharmaceuticals & Drugs industry, where valuation, profitability and peer comparison all influence how a stock is read on a weak day.

The current snapshot also shows a mixed profile. The company’s price-to-book ratio is 3.63, RSI is 58.42, 50-day DMA is 211.8 and 200-day DMA is 175.94. At the same time, profitability indicators remain soft, with ROE at -4.04, ROCE at 1.24 and EPS at -2.36. That combination makes the stock worth tracking not only for price action, but also for whether fundamentals begin to support valuation more convincingly.

Piramal Pharma (PPLPHARMA) Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 212.2
Previous Close	Rs 218.1
Today's Move	-Rs 5.90 (-2.71%)
Open	Rs 217.75
High	Rs 218.7
Low	Rs 212
Turnover	Rs 4.07 crore
Market Capitalisation	Rs 30,168.35 crore
Market Cap Category	Large Cap

Piramal Pharma Share Price opened at Rs 217.75, touched a day high of Rs 218.70 and then moved down to Rs 212.00 before trading at Rs 212.20. That means the stock was hovering just above the session low at the captured time, suggesting that selling pressure persisted through the day instead of being to the opening trade.

The fall of Rs 5.90 or 2.71% also needs to be read alongside turnover of Rs 4.07 crore. The supplied figures confirm meaningful activity, although they do not attribute the move to a specific disclosure or event. For a company with a market value above Rs 30,000 crore, daily moves are often interpreted through the lens of broader sentiment, technical levels and relative fundamentals rather than price alone.

On momentum, the RSI of 58.42 does not indicate an extreme reading. Meanwhile, the stock is trading close to its 50-day DMA of 211.8 and above its 200-day DMA of 175.94. That leaves the short-term setup under pressure on the day, while the longer-term moving-average reference remains below the current market price.

Piramal Pharma (PPLPHARMA) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 30,168.35 crore
P/B Ratio	3.63x
ROE	-4.04%
ROCE	1.24%
EPS	Rs -2.36
Book Value Per Share	Rs 60.13
Dividend Yield	0%

Piramal Pharma Share Price is being evaluated against a balance-sheet-based valuation that is neither very low nor very stretched by sector standards. The P/B ratio stands at 3.63, while book value per share is Rs 60.13. In simple terms, the market is valuing the stock at several times its accounting book value, so investors would normally expect operating returns to justify that premium over time.

That is where the current numbers look weaker. ROE is -4.04, ROCE is 1.24 and EPS is -2.36. Those figures indicate negative returns on equity, low capital efficiency and negative earnings per share in the supplied snapshot. Dividend yield is 0, so there is no dividend support visible in the data provided here.

This creates a familiar tension in the stock’s profile: sizeable market presence and moderate valuation on one side, but soft profitability on the other. When a stock with these traits falls in a single session, market participants often focus less on the percentage move itself and more on whether future business performance can narrow the gap with stronger peers.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Benchmark Median P/E	32.79x
Benchmark Average P/E	49.1x
Benchmark P/E Range	3.4x to 706.55x
Company P/B Ratio	3.63x
Benchmark Median P/B	3x
Benchmark Average P/B	4.44x
Company ROE	-4.04%
Benchmark Median ROE	11.83%
Benchmark Average ROE	11.27%
Company ROCE	1.24%
Benchmark Median ROCE	13.75%
Benchmark Average ROCE	13.75%
Company Market Capitalisation	Rs 30,168.35 crore
Benchmark Median Market Cap	Rs 759.52 crore
Benchmark Average Market Cap	Rs 14,312.16 crore

The sector benchmark covers 200 companies in the same Pharmaceuticals & Drugs industry, making it a useful context for today’s move. P/E data is available for 169 of them, with a median of 32.79, an average of 49.1, a minimum of 3.4 and a maximum of 706.55. Piramal Pharma does not have a supplied P/E figure here because EPS is negative, so price-to-book and return ratios become more practical reference points.

On P/B, the company’s 3.63 sits above the industry median of 3 but below the average of 4.44 across 199 companies. That suggests the stock is not an outlier on this valuation measure. The sharper contrast appears in profitability: ROE of -4.04 is well below the industry median of 11.83 and average of 11.27, while ROCE of 1.24 is also far below the median and average of 13.75.

Scale remains a major positive. The industry median market cap is Rs 759.52 crore and the average is Rs 14,312.16 crore, whereas Piramal Pharma stands at Rs 30,168.35 crore. So the company is materially larger than the typical listed peer in the benchmark set, even though its current return ratios lag the group.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Sun Pharmaceutical Industries	SUNPHARMA	4,51,338.9	37.06	5.18	14.85	19.11
Divi's Laboratories	DIVISLAB	2,54,068.03	86.06	14.25	16.19	21.51
Torrent Pharmaceuticals	TORNTPHARM	1,88,767.06	86.01	20.9	26.76	19.27
Zydus Lifesciences	ZYDUSLIFE	1,14,712.94	24.95	4.18	19.69	21.39
Cipla	CIPLA	1,11,803.57	32.79	3.14	11.83	16

The supplied peer set highlights the same pattern. Sun Pharmaceutical Industries has market cap of Rs 4,51,338.9 crore with ROE of 14.85 and ROCE of 19.11. Divi's Laboratories and Torrent Pharmaceuticals have much higher P/B multiples at 14.25 and 20.9, but also stronger return ratios. Zydus Lifesciences shows P/E of 24.95, P/B of 4.18, ROE of 19.69 and ROCE of 21.39, while Cipla stands at P/E 32.79, P/B 3.14, ROE 11.83 and ROCE 16.

Against that backdrop, Piramal Pharma’s P/B of 3.63 is not far from some established peers, especially Cipla and Zydus. The bigger difference is profitability. Negative ROE and low ROCE make the company look weaker on operating returns than the comparison group provided here, which helps explain why investors may keep watching execution metrics closely when the stock turns lower.

Why Investors Are Watching Piramal Pharma

• Price action: The stock fell 2.71% to Rs 212.20 and traded close to the day’s low of Rs 212.00.
• Large-cap position: Market capitalisation remains substantial at Rs 30,168.35 crore.
• Technical context: RSI is 58.42, the price is near the 50-day DMA of 211.8 and above the 200-day DMA of 175.94.
• Valuation context: P/B of 3.63 is above the industry median of 3 but below the average of 4.44.
• Profitability context: ROE of -4.04, ROCE of 1.24 and EPS of -2.36 remain weaker than sector medians and major peers.

About Piramal Pharma

Piramal Pharma is part of the Healthcare sector and operates in the Pharmaceuticals & Drugs industry. Based on the supplied market snapshot, it is classified as a Large Cap company with market capitalisation of Rs 30,168.35 crore. That places it well above the median company size in the benchmark universe, making it an important listed name within the broader pharma space.

Track Piramal Pharma Share Price on Univest

UsePiramal Pharma (PPLPHARMA) live share-price page,Univest top decliners screener,Univest market blogsto review live stock data, top decliners and related market analysis.

Investors tracking Piramal Pharma Share Price can use those pages to monitor live price movement, valuation data, market-cap changes and sector context in one place. The available snapshot supports a measured reading: the stock is down on the day, remains sizeable within its industry and is being assessed against a profitability profile that is still below key benchmarks.

Frequently Asked Questions

Why is Piramal Pharma Share Price falling today?

Ans. The stock was down 2.71% at Rs 212.20 on 10 September 2026. The supplied data confirms the decline and weak intraday trend, but it does not identify a company-specific catalyst.

What is Piramal Pharma Share Price Today?

Ans. Piramal Pharma Share Price Today stood at Rs 212.20 at 3:23:03 PM IST. That was Rs 5.90 below the previous close of Rs 218.10. The stock moved 2.71% lower during the session.

What does Piramal Pharma’s P/B ratio indicate?

Ans. Its P/B ratio is 3.63, compared with the industry median of 3 and average of 4.44. That places it above the median but below the average on this valuation measure.

How does Piramal Pharma compare with major pharma peers?

Ans. Its P/B ratio is broadly comparable with some peers, but its ROE and ROCE are weaker than companies such as Sun Pharma, Zydus Lifesciences and Cipla in the supplied comparison set.